Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KPTI stock hub

Karyopharm Therapeutics Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KPTIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

194.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KPTI

In the news

Latest news · KPTI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-119.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KPTI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001503802
Company name	Karyopharm Therapeutics Inc.
Country	United States
Country code	US
Cusip	48576U205
Employees	228
Employees Change	-51%
Employees Change Percent	-18.28
Enterprise value	$437M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2013-11-06
Isin	US48576U2050
Last refreshed	2026-05-10
Market cap	$194.8M
Market cap category	Micro-Cap
Price	$8.64
Price currency	USD
Rev Per Employee	640,644.74x
Sector	Healthcare
Sic	2834
Symbol	KPTI
Website	https://www.karyopharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-100.65%
EV Sales Forward	3.12x
EV/Sales	2.99x
FCF yield	-38.7%
P/S ratio	1.33x
PS Forward	1.39x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-62.1%
EBITDA Margin	-61.9%
Gross margin	9.93%
Gross Profit	$14.5M
Gross Profit Growth3 Y	65.5%
Gross Profit Growth5 Y	-32.74%
Net Income	$-196M
Net Income Growth Years	0%
Pretax Margin	-134.18%
Profit Margin	-134.21%
Profit Per Employee	$-859,820
ROA	-41.56
Roa5y	-30.43
ROCE	-554.6
ROIC	-119.3

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-23.03%
Cagr1y	41.44%
Cagr3y	-40.31%
Cagr5y	-41.49%
EPS Growth Years	0
Revenue Growth	0.57x
Revenue Growth Q	11.58x
Revenue Growth Quarters	2x
Revenue Growth Years	1x
Revenue Growth3 Y	-2.39x
Revenue Growth5 Y	6.21x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.07
Assets	$108.4M
Cash	$63.7M
Current Assets	$103.1M
Current Liabilities	$92.1M
Debt	$305.9M
Equity	$-292.9M
Interest Coverage	-1.98
Liabilities	$401.3M
Long Term Assets	$5.3M
Long Term Liabilities	$309.3M
Net Cash	$-242.2M
Net Cash By Market Cap	$-124
Tangible Book Value	$-292.9M
Tangible Book Value Per Share	$-16
WACC	10.62

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.12
Inventory Turnover	29.98
Net Working Capital	$-30.7M
Quick ratio	0.98
Working Capital	$11.1M
Working Capital Turnover	$3.88

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-29.33%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-92.7%
1Y total return	41.41%
200-day SMA	6.77
3Y total return	-78.75%
50-day SMA	8.01
50-day SMA vs 200-day SMA	50over200
5Y total return	-93.14%
All Time High	735.1
All Time High Change	-98.82%
All Time High Date	2014-12-08
All Time Low	3.51
All Time Low Change	146.15%
All Time Low Date	2025-04-01
ATR	0.6
Beta	0.81
Beta1y	1.97
Beta2y	1.74
Ch YTD	17.39
High	9
High52	10.99
High52 Date	2026-02-24
High52ch	-21.38%
Low	8.54
Low52	3.65
Low52 Date	2025-08-11
Low52ch	136.71%
Ma50ch	7.93%
Price vs 200-day SMA	27.57%
RSI	52.76
RSI Monthly	42.33
RSI Weekly	55.74
Sharpe ratio	0.78x
Sortino ratio	1.39
Total Return	-29.33%
Tr YTD	17.39
Tr1m	19.83%
Tr1w	-1.48%
Tr3m	38.02%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	1
Analyst Price Target Top	$15
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-1.44
Earnings Revenue Estimate	31,905,432x
Earnings Revenue Estimate Growth	6.3x
Operating Income	$-90.7M
Operating margin	-62.1
Price target	$16.83
Price Target Change	$94.79
Price Target Change Top	$73.61

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	18,536,499%
Float Percent	82.23%
Net Borrowing	27,000,000
Shares Insiders	0.62%
Shares Institutions	46.34%
Shares Out	22,543,316
Shares Qo Q	106.53%
Shares Yo Y	29.33%
Short Float	30.85%
Short Ratio	3.37
Short Shares	25.37

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-89.4M
Average Volume	371,947.1x
Bv Per Share	-16
Ch10y	-92.7
Ch1m	19.83
Ch1w	-1.48
Ch1y	41.41
Ch3m	38.02
Ch3y	-78.75
Ch5y	-93.14
Ch6m	67.44
Change	-2.37%
Change From Open	-2.59
Close	8.85
Days Gap	0.23
Depreciation Amortization	296,000
Dollar Volume	2,552,567
Earnings Date	2026-05-14
Earnings Time	bmo
EBIT	$-90.7M
EBITDA	$-90.4M
EPS	$-17.93
F Score	3
FCF	$-75.4M
FCF EV Yield	-17.25x
FCF Per Share	$-3.34
Financing CF	30,048,000
Fiscal Year End	December
Founded	2,008
Income Tax	$43,000
Investing CF	43,378,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-02-12
Last Report Date	2025-12-31
Last Split Date	2025-02-26
Last Split Type	Reverse
Last10k Filing Date	2026-02-13
Ma150	7.12
Ma150ch	21.33%
Ma20	8.78
Ma20ch	-1.58%
Net CF	-1,923,000
Next Earnings Date	2026-05-14
Open	8.87
Optionable	Yes
Position In Range	21.74
Post Close	8.64
Postmarket Change Percent	-2.2
Postmarket Price	$8.45
Ppne	4,652,000
Price Date	2026-05-08
Relative Volume	0.79x
Revenue	146,067,000x
SBC By Revenue	9.62x
Share Based Comp	14,050,000
Tax By Revenue	0.03x
Tr6m	67.44%
Us State	Massachusetts
Volume	295,436
Z Score	-23.92

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KPTI pay a dividend?

Capital-return profile for this ticker.

Performance

KPTI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KPTI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+46.3%

Float: +82.2% of shares outstanding

Insider ownership

+0.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KPTI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.8

Neutral momentum band

Price vs 200-day MA

+27.6%

50/200-day relationship not available

Beta (5Y)

0.81

Moves roughly with the market

Sharpe ratio

0.78

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KPTI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KPTI stock rating?

Karyopharm Therapeutics Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KPTI analysis?

The full report lives at /stocks/KPTI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KPTI?

The latest report frames KPTI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KPTI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.